Form 4: Cabaletta Bio Director Tomasello Receives Repriced Stock Options

Director Shawn Tomasello receives repriced stock options from Cabaletta Bio, Inc. following board approval.

Summary

• Shawn Tomasello, a director at Cabaletta Bio, Inc., received repriced stock options on May 19, 2025.
• The Issuer's board of directors approved an option repricing on May 15, 2025, effective May 19, 2025.
• Tomasello received 44,000 options with an exercise price of $1.92 and another 22,000 options with an exercise price of $1.92.
• The repricing was exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act.
• The options are subject to a vesting schedule and continued service with the Issuer.
• A 'Retention Period' is in effect, ending one year after the Repricing Date, upon a Sale Event, or termination of service due to death or disability.

Sentiment

Score: 7

Explanation: The document describes a routine stock option repricing, which is generally a neutral event. The repricing could be seen as a positive sign that the company is trying to retain key personnel, but it also suggests that the stock price may have underperformed expectations.

Positives

• The option repricing could incentivize the director to remain with the company.
• The repricing is exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act.

Risks

• If Tomasello's service is terminated before the end of the Retention Period (excluding death or disability), the benefit of the repriced options may be lost.

Future Outlook

The options become exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Industry Context

Stock option repricing is a tool companies use to re-incentivize employees or directors when the stock price has fallen below the original option exercise price. This is a common practice in the biotech industry to retain key personnel.

Comparison to Industry Standards

• Stock option grants and repricings are common practices in the biotechnology industry to attract and retain talent.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their compensation packages.
• The vesting schedules and terms of these options are generally in line with industry standards, often tied to continued service and company performance.

Stakeholder Impact

• Shareholders may view the repricing as a positive sign that the company is trying to retain key personnel.
• The director is incentivized to remain with the company and contribute to its success.

Key Dates

Keywords

stock options, Cabaletta Bio, director, Shawn Tomasello, repricing, Form 4, beneficial ownership